• Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    • Interviews – Academia
    • Interviews – Industry
  • Issues
  • Subscribe
  • Board
  • Advertise
Facebook Twitter Instagram
Trending
  • Highlights of India’s first Biotech startup Expo
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid
  • Moderna and Pfizer: Lawsuits and Charitable Giving
  • European Commission Approves Two GM Crops for Food and Feed
Biotech Express Magazine
  • Home
  • Articles
  • COVID-19
  • News
    • Biotech News – Featured
    • Biotech News
    • BioGadgets
  • Interviews
    1. Interviews – Academia
    2. Interviews – Industry
    Featured
    January 16, 20211

    Interview – Prof Rajeev K Varshney “The Youngest Indian Scientist (47)” who achieved an h-index of 100 recently

    Recent
    March 30, 2022

    Interview- Bioenergy: India’s Ministry of New and Renewable Energy started almost four decades ago…but did not catch up…, Professor Ashok Pandey

    January 24, 2022

    Interview: Prof Kailash Chander Bansal, Secretary, National Academy of Agricultural Sciences (NAAS), India

    January 23, 2022

    Interview – Dr Heera Lal: How an IAS officer using Biotech approaches to transform Indian villages into “Organic Villages”

  • Issues
  • Subscribe
  • Board
  • Advertise
Biotech Express Magazine
You are at:Home»Articles»Guest Article – Leprosy Drug Clofazimine Set For New Roles

Guest Article – Leprosy Drug Clofazimine Set For New Roles

0
By Biotech Express on August 17, 2021 Articles, Articles- Guestorials, SARS- CoV2 & COVID-19 Updates

Nabanita Das, PhD
Email: dasnabanita123@gmail.com
SERB-National Postdoctoral fellow, CSIR-Central Drug Research Institute, Sector-10, Jankipuram extension, Sitapur Road, Lucknow-22603, Uttar Pradesh. India.

Abstract
Development of a brand new drug takes enormous toll on time, money and effort, due to bottlenecks in therapeutic development. Strategically repurposing drugs for other uses can save time and money, as their pharmacology, formulation and potential toxicity are already known. The preclinical phase includes a demonstration of its efficacy in invitro or in vivo model system and then filing the experimental new drug application with the U.S. Food and Drug Administration (FDA), it typically enters into clinical phase II trials. The cost of launching a repurposed drug is approximately 85% less than for a de novo drug. Besides repurposed drugs, repositioned and rescued drugs generate 25% of annual revenues for the pharmaceutical industry as per the estimate. There are multiple illustrations of drug repurposing to date, the pioneer was the repurposing of thalidomide, initially a sedative and anti-leprosy, later approved for the treatment of multiple myeloma by USFDA in 2012.

Clofazimine (CFZ), primarily known for its anti-leprosy activity is shown to be effective against primary interventions for multidrug-resistant tuberculosis, chronic myelogenous leukemia (CML), and more recently SARS-CoV-2. CFZ was discovered during 1950s at Trinity College, Dublin, was approved for use in the United States in 1986, presently it is in WHO list of essential medicines.

The efficacy of CFZ against Mycobacterium Avium Complex (MAC) was demonstrated by Jarand et. al. from University of Calgary, Canada in 2016. CFZ administered in combination with macrolide and ethambutol was shown to be highly effective in treatment of MAC. The work was recognized and published in the renowned journal CHEST.

The research group at CSIR-Central Drug Research Institute, Lucknow in collaboration with Zydus Research Centre, Ahmedabad and King Georges Medical University, Lucknow has demonstrated that CFZ can defeat leukemic stem cells (LSCs) and resists relapse in CML patients.

CML, a type of cancer affecting blood and bone marrow developed due to chromosomal aberrations is one of most recurrent adult leukemia in Indian population, which accounts for 30%-60% of all leukemia. The management of CML was revolutionized by the targeted treatment with imatinib that has become the standard treatment of choice. The second-generation of medicine includes nilotinib, dasatinib administered to patients resistant or intolerant to first-generation of drugs. However, although effective, second-line therapy comes at a significant expense. It has been estimated that the cost can measure up to $800000 per quality-adjusted life-year compared to generic imatinib. Moreover, a considerable number of patients suffer from relapse and progression when the first/second-line therapy stops due to the activity of leukemic stem cells (LSCs).

The breakthrough research from the group shows CFZ is particularly effective in imatinib-resistant patients and terminates LSCs including notorious quiescent stem cells derived from CML patients without causing harm to hematopoietic cells derived from healthy individuals. The drug could successfully over empower cellular leukemic/oncogenic factors often associated with multidrug-resistant patients. Interestingly CFZ when administered in combination with imatinib at a significantly low physiological dose known so far, proved exceptionally effective in comparison to monotherapy. The outcome of the study was published in a reputed journal, HAEMATOLOGICA. Leukemic stem cells possess immense hindrance to the existing drugs, as they are incapable of targeting quiescent stem cells. The identified drug from the study could overcome this hindrance and can be proposed for its further clinical evaluation.

The future of this comprehensive study depends directly on clinical evaluation in humans because preclinical validations, pharmacokinetics and toxicity studies have already been performed in detail. Successful execution of clinical trials will render healthcare much more affordable for CML patients of Indian origin. The research team with their disease-centric viewpoint screened over most possible repurposing candidates for the treatment of chronic myeloid leukemia and has come across CFZ. Again, they have explored the use of novel combination therapies, where the repurposed drug increases the efficiency of imatinib, a well-known treatment and could dramatic improvements in outcomes. This research promises that in the future treatment of CML who are resistant to existing drugs or relapse patients will benefit from it as the cure will become within reach in economically backward parts of India. Clinicians can bank on CFZ repurposing for the treatment of chronic myeloid leukemia.

Most recently in 2020, researchers from Sanford Burnham Prebys Medical Discovery Institute and the University of Hong Kong demonstrated that CFZ was capable of inhibiting SARS-CoV-2 multiplication in hamsters. Their research published in the highly reputed journal NATURE reports CFZ to be effective against several coronaviruses in including the novel coronavirus. Novel emerging infectious diseases like the present COVID-19 possess extreme challenges to the healthcare systems. This creates an urgent need for effective pharmacological treatments. The demand can only be fulfilled by repurposing drugs due to the lack of available time for new drug formulation. The antiviral synergism between clofazimine and remdesivir, the first ever-pharmacological approach towards prevention of Covid-19 has a promising future. Repurposing clofazimine thus brings a ray of hope for combating the prevalent pandemic situation.

References:
1. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Alan Talevi and Carolina L Bellera. Expert Opin Drug Discov. 2020 Apr;15(4):397-401.
2. Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. Julie Jarand, J Paul Davis, Robert L Cowie, Stephen K Field, Dina A Fisher. Chest. 2016 May;149(5):1285-93.
3. Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells. Sabyasachi Sanyal et. al. Haematologica 2020 Apr;105(4):971-986.
4. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. Kwok-Yung Yuen et. al. Nature. 2021 May;593(7859):418-423.

 

 

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Biotech Express
  • Website
  • Facebook
  • Twitter
  • LinkedIn

ISSN: 2454-6968 | Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports, Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology, Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurosciences, Genetics, Medical Sciences, BioPharma etc.

Related Posts

Researchers who jumped into the field from distant disciplines published lower impact work, study finds

Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid

No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible?

Leave A Reply Cancel Reply

Current Issue – May 2022

                   VIEW SUBSCRIPTION PLANS

JOBS/NOTIFICATIONS

   

         CLICK HERE FOR RECENT NOTICES

Recent Posts
  • Highlights of India’s first Biotech startup Expo June 13, 2022
  • NTU Singapore scientists develop a ‘fabric’ that turns body movement into electricity June 6, 2022
  • Researchers who jumped into the field from distant disciplines published lower impact work, study finds May 30, 2022
  • Amrita Vishwa Vidyapeetham gets CDSCO nod for clinical trials of first-of-its-kind synthetic jaw-bone graft May 26, 2022
  • AstraZeneca Covid-19 vaccines which uses a chimpanzee adenovirus inked to monkeypox outbreak May 25, 2022
  • Concerns Mount Over COVID-19 ‘Rebounds’ After Treatment With Pfizer’s Paxlovid May 25, 2022
  • Moderna and Pfizer: Lawsuits and Charitable Giving May 25, 2022
  • European Commission Approves Two GM Crops for Food and Feed May 25, 2022
  • Ayush Ministry, DBT sign MoU for cooperation on evidence-based biotech interventions in Ayush sector May 24, 2022
  • CCI, India merger approved absorption of Covidshield Technologies into Biocon Biologics May 20, 2022
  • No Vaccine Mandates after supreme court order, next compensation to AEFI survivors from COVID Vaccine makers possible? May 19, 2022
  • Industry lobbying on WHO overshadowing public health policy, researchers suggest May 18, 2022
  • Letter: Public Health Bill to be presented in the Monsoon session 2022 is Illegal, Unconstitutional and Arbitrary: Dr Maya Valecha May 15, 2022
  • Paid publishing in science has killed peer review system, says CSIR’s ex-chief Shekhar Mande May 15, 2022
  • Bill Gates tests positive for COVID-19 even after many booster doses, mocked on twitter May 10, 2022
  • Another Ivermectin COVID-19 paper retracted May 8, 2022
  • COVID-19 spike protein paper retracted May 7, 2022
  • Killer Music? Can sound make a clot in a boy who died while dancing or it is related to COVID vaccination May 7, 2022
  • Clotting Risks Cause FDA to Restrict Use of J&J COVID Vaccine May 6, 2022
  • Department of Pharmaceuticals releases “Common Guidelines on Pharmaceutical Innovation and Entrepreneurship” for academic institutions May 6, 2022
  • No medical care for 45% of recorded deaths in 2020, highest ever in India: New data May 6, 2022
  • Indian opposition seeks higher compensation for COVID deaths after damning WHO report May 6, 2022
  • Redcliffe Lifetech raises $61 million in Series B funding May 6, 2022
  • Engineers Create an Enzyme That Breaks Down Plastic Waste in Hours, Not Decades May 5, 2022
  • Eris Lifesciences acquires 100% stake in Oaknet Healthcare for Rs 650 cr May 5, 2022
  • The Union Government has Lied to the Supreme Court in COVID Vaccines Case? May 5, 2022
  • COVID-19- vitamin D paper from India retracted by Springer Nature journal May 4, 2022
  • IISc develops 3D printed gloves for rehabilitating stroke patients May 4, 2022
  • A new wearable technology — for plants May 4, 2022
  • Sanofi India names Rodolfo Hrosz managing director effective June 1 May 4, 2022
Archives
Categories
  • Articles
  • Articles- Editorials
  • Articles- Guestorials
  • BioControversial
  • BioEvents
  • BioGadgets
  • BioPolicies
  • BioResearch – Academic
  • Biotech News
  • Biotech News – Featured
  • Contents
  • Interviews
  • Interviews – Academia
  • Interviews – Industry
  • SARS- CoV2 & COVID-19 Updates
  • startups
About Us

Biotech Express Magazine publishes articles in the field of biotechnology and allied sciences in a way that have never been presented earlier. It publishes Editorials, Guest Articles, Reports,  Interviews, Current News of Govt. Academics and Business, Research Highlights and Notifications of Events, Jobs, Research Proposals in the field of Biotechnology and allied sciences like Biological Sciences, Life Sciences, Microbiology, Biochemistry, Neurology, Genetics, Medical Sciences, BioPharma etc.

Call us: _91-9311986177

Email – biotechexpressindia@gmail.com

About Us

About Biotech Express

Advisory and Editorial Board

Contact Us

Policy and Guidelines

Submission policies

Peer review policy    

Copyright policy

 

Follow Us
  • Facebook
  • Twitter
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies. Copyright © 2013-2020 Biotech Express except certain content provided by third parties.

Type above and press Enter to search. Press Esc to cancel.